ReviewCureus2026
Literature Review of Occult Hepatitis B Infection and Hepatitis B Core Antibody-Positive Blood Donors.
Review in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B virus (HBV) is one of transfusion-transmissible infection that is screened routinely in blood centers by serology and/or nucleic acid testing (NAT). Serology tests for HBV include antibody to hepatitis B core antigen (anti-HBc) and hepatitis B surface antigen (HBsAg). Blood centers around the world differ in their procedures for screening for HBV in blood donors. In high-income, HBV non-endemic countries, anti-HBc, HBsAg, and pooled NAT are usually used to screen blood donors, while in HBV endemic countries, anti-HBc is not usually used because it would lead to high discard rates. Donors who test positive only for anti-HBc have a history of HBV infection but have cleared the virus, resulting in negative results for both HBsAg and NAT. Deferral policy for anti-HBc-positive-only donors is restricted only to donors with high titers of anti-HBc and low titers of the protective antibody to hepatitis B surface antigen (anti-HBs) in some countries. In HBV endemic countries that screen for HBV by HBsAg and NAT, some blood donors test positive for HBsAg but negative for NAT (NAT yield donors). These test results can be the result of window period infection or occult hepatitis B infection (OBI), defined as the presence of replication-competent HBV DNA in the liver - in the presence or absence of HBV DNA in the blood - of individuals testing negative for HBsAg assessed by currently available assays. OBI donors can transmit HBV to recipients by blood transfusion. Therefore, in HBV endemic countries, individual donation NAT (ID-NAT) should be used to screen blood donors because it is more sensitive than pooled NAT and can detect both window period infection and OBI, while anti-HBc cannot detect window period infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.